Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 991.96M -17.5% |
| Revenue (ttm) | 1.66B +0.8% |
| Net Income | 13.01M |
| EPS | 0.17 |
| Shares Out | 77.80M |
| PE Ratio | 75.92 |
| Forward PE | 5.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,038,755 |
| Open | 12.75 |
| Previous Close | 12.83 |
| Day's Range | 12.33 - 12.86 |
| 52-Week Range | 8.70 - 20.49 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 15.67 (+22.9%) |
| Earnings Date | Oct 21, 2026 |
About IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after... [Read more]
Financial Performance
In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $15.67, which is an increase of 22.90% from the latest price.
News
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congre...
Integra LifeSciences price target lowered to $14 from $19 at UBS
UBS lowered the firm’s price target on Integra LifeSciences (IART) to $14 from $19 and keeps a Neutral rating on the shares.
Integra LifeSciences price target lowered to $13 from $15 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Integra LifeSciences (IART) to $13 from $15 and keeps a Hold rating on the shares. Integra LifeSciences’ Q3 results were…
Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover those losses. The Law Offices o...
Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Integra LifeSciences Holdings Corporation ("Integra" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz ...
Integra LifeSciences price target lowered to $14 from $15 at BMO Capital
BMO Capital analyst Vik Chopra lowered the firm’s price target on Integra LifeSciences (IART) to $14 from $15 and keeps a Market Perform rating on the shares. The firm’s post-earnings…
Integra LifeSciences price target lowered to $14 from $17 at JPMorgan
JPMorgan lowered the firm’s price target on Integra LifeSciences (IART) to $14 from $17 and keeps an Underweight rating on the shares.
Integra LifeSciences price target lowered to $13 from $15 at Wells Fargo
Wells Fargo lowered the firm’s price target on Integra LifeSciences (IART) to $13 from $15 and keeps an Equal Weight rating on the shares. The firm notes Q3 results came…
Integra LifeSciences price target lowered to $14 from $15 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Integra LifeSciences (IART) to $14 from $15 and keeps a Neutral rating on the shares. The firm updated the company’s…
Integra LifeSciences price target lowered to $22 from $25 at Citizens
Citizens analyst Daniel Stauder lowered the firm’s price target on Integra LifeSciences (IART) to $22 from $25 and keeps an Outperform rating on the shares. Integra cut FY26 guidance after…
Integra LifeSciences Holdings Earnings Call Transcript: Q3 2026
Q3 growth and EPS gains were tempered by Cincinnati flooding and Tissue Reconstruction softness. Record cash flow, lower leverage, and refinancing strengthened flexibility as recovery and 2027 growth remain priorities.
Integra LifeSciences Holdings Slides: Q3 2026
Integra LifeSciences Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 21, 2026.
Integra LifeSciences Holdings Earnings release: Q3 2026
Integra LifeSciences Holdings released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Integra LifeSciences Holdings Quarterly report: Q3 2026
Integra LifeSciences Holdings has published its Q3 2026 quarterly earnings report on October 21, 2026.
Integra LifeSciences Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third...
Integra Announces Completion of Refinancing Transactions
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal a...
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting
PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Americ...
Integra LifeSciences price target lowered to $15 from $19 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Integra LifeSciences (IART) to $15 from $19 and keeps a Hold rating on the shares as part of a broader…
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial resu...
Integra LifeSciences price target lowered to $15 from $18 at BMO Capital
BMO Capital lowered the firm’s price target on Integra LifeSciences (IART) to $15 from $18 and keeps a Market Perform rating on the shares. The firm is adjusting its target…
Integra LifeSciences price target lowered to $15 from $19 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Integra LifeSciences (IART) to $15 from $19 and keeps a Neutral rating on the shares. The firm adjusted targets in…
Integra LifeSciences price target lowered to $15 from $18 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Integra LifeSciences (IART) to $15 from $18 and keeps an Equal Weight rating on the shares. The company preannounced…
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)
A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into...
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary t...
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 ...